Draft:Centrient Pharmaceuticals
Submission declined on 12 June 2024 by Vanderwaalforces (talk). This submission appears to read more like an advertisement than an entry in an encyclopedia. Encyclopedia articles need to be written from a neutral point of view, and should refer to a range of independent, reliable, published sources, not just to materials produced by the creator of the subject being discussed. This is important so that the article can meet Wikipedia's verifiability policy and the notability of the subject can be established. If you still feel that this subject is worthy of inclusion in Wikipedia, please rewrite your submission to comply with these policies.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|
Centrient Pharmaceuticals
[edit]Centrient Pharmaceuticals is a leading global business-to-business pharmaceutical company specializing in the production of sustainable antibiotics, next-generation statins, and anti-fungals. The company is renowned for its commitment to innovation and sustainability in pharmaceutical manufacturing.
History
[edit]Centrient Pharmaceuticals traces its roots back to 1869. Originally established as ‘Nederlandsche Gist- en Spiritusfabriek’, the company later became known as Gist Brocades and then DSM Sinochem Pharmaceuticals. In 2018, Bain Capital acquired the company and it was rebranded as Centrient Pharmaceuticals.[1]
Headquarters and Global Network
[edit]The company is headquartered in Rijswijk, Netherlands, and operates manufacturing sites and sales offices across the globe. Key manufacturing locations include Delft in the Netherlands, Santa Perpètua de Mogoda in Spain, Toansa in India, Ramos Arizpe in Mexico, and two sites in China located in Changchun and Zibo. Sales offices are located in multiple regions including North America, Latin America, Europe, and Asia.[2]
Products
[edit]Centrient's product portfolio includes:
- Antibiotics: Including various penicillins and cephalosporins.
- Statins: Used for managing cholesterol levels.
- Anti-fungals: Such as Nystatin.[3]
The company produces both active pharmaceutical ingredients (APIs) and finished dosage forms (FDFs), ensuring a comprehensive supply of essential medicines.[4]
Enzymatic Production Innovation
[edit]Centrient Pharmaceuticals is known for pioneering the enzymatic production of penicillins and cephalosporins. This process involves the use of enzymes to catalyze chemical reactions in the production of these antibiotics, making the process more environmentally friendly and efficient compared to traditional chemical synthesis. The enzymatic method reduces the use of harmful solvents and lowers energy consumption, aligning with the company's sustainability goals. This innovation has positioned Centrient as a leader in sustainable antibiotic production.[5]
Vertically Integrated Manufacturer
[edit]Centrient is the only vertically integrated Western-based merchant antibiotic manufacturer. This means they produce the fermentative intermediate, the final API, and the finished dose in Western countries. As a business-to-business merchant player, Centrient supplies many major global and leading regional pharmaceutical companies with APIs and FDFs.[6]
Purpose and Sustainability Initiatives
[edit]Centrient's purpose is to improve lives through innovative and sustainable manufacturing of medicines, saving the lives of millions of people worldwide annually. The company employs advanced wastewater treatment technologies, such as Mechanical Vapor Recompression (MVR), to enhance water recovery and reduce environmental impact. Their Toansa site in India exemplifies their commitment to environmental stewardship.[7]
Recent Developments
[edit]In October 2023, Centrient partnered with Almirall to join its innovation hub in Barcelona. This collaboration aims to enhance Centrient’s research and development capabilities, focusing on biotechnology, strain and enzyme development, and sustainable manufacturing processes.[8]
Leadership
[edit]The current CEO of Centrient Pharmaceuticals is Rex Clements, who took over the role in March 2020. Clements has a dual MBA in Strategy and General Management from the Wharton School of the University of Pennsylvania, and a Bachelor of Science in Chemical Engineering from the University of Stellenbosch. Before joining Centrient, he held several senior roles at Sandoz, a division of Novartis.[9][10]
References
[edit]- ^ "Our History". Centrient Pharmaceuticals. Retrieved 2024-06-12.
- ^ "Our Global Network". Centrient Pharmaceuticals. Retrieved 2024-06-12.
- ^ "Our Products". Centrient Pharmaceuticals. Retrieved 2024-06-12.
- ^ "Our Products". Centrient Pharmaceuticals. Retrieved 2024-06-12.
- ^ "Leadership". Centrient Pharmaceuticals. Retrieved 2024-06-12.
- ^ "Leadership". Centrient Pharmaceuticals. Retrieved 2024-06-12.
- ^ "Centrient's Toansa Manufacturing Site in India Leads the Way in Wastewater Management". Centrient Pharmaceuticals. Retrieved 2024-06-12.
- ^ "Centrient Pharmaceuticals joins Almirall's growing innovation hub in Barcelona". Almirall. Retrieved 2024-06-12.
- ^ "Leadership". Centrient Pharmaceuticals. Retrieved 2024-06-12.
- ^ "Centrient Pharmaceuticals appoints Rex Clements as Chief Executive Officer after Karl Rotthier decides to step down from the role". Centrient Pharmaceuticals. Retrieved 2024-06-12.
External Links
[edit]- [Official website](https://www.centrient.com)
- [Almirall Partnership Announcement](https://www.almirall.com/media/centrient-pharmaceuticals-joins-almirall-innovation-hub)
- in-depth (not just brief mentions about the subject or routine announcements)
- reliable
- secondary
- strictly independent of the subject
Make sure you add references that meet all four of these criteria before resubmitting. Learn about mistakes to avoid when addressing this issue. If no additional references exist, the subject is not suitable for Wikipedia.